Chulpanova D.S.; Solovyeva V.V.; James V.; Arkhipova S.S.; Gomzikova M.O.; Garanina E.E.; Akhmetzyanova E.R.; Tazetdinova L.G.; Khaiboullina S.F.; Rizvanov A.A.
(2020)
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. High-dose recombinant interleukin 2 (IL2) therapy has been shown to be successful in renal cell carcinoma and metastatic melanoma. However, systemic administration ...